drugset / Trial / NCT03424408

Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin

NCT03424408 ↗

Completed 20 enrolled Hamilton Health Sciences Corporation
NaSingle-groupOpen-labelDiagnostic

Summary

Some aspirin-treated patients have a blunted pharmacological response predisposing to clinical failure. The investigators hypothesize that the blunted response often results from increased rate of platelet production and some failures will be prevented by administering aspirin twice daily. The overall objective is to develop a valid method to quantify platelet production (without the use of radioactive isotopes) in order to examine the hypothesis that enhanced platelet production is a common cause of poor aspirin responsiveness in patients with atherothrombosis.

Timeline

Start
2018-03-01
Primary completion
2019-09-03
Completion
2019-09-03

Drugs

EvaluationDrugModalityDoseRoute
Background Aspirin Small molecule 81 mg —

Indications